This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
We want to thank Brodell and Pokorney for raising some important questions emerging from our study. Their first concern was the potential establishment of restrictive policies by insurance or managed care companies to prohibit payment for the removal and pathologic examination of fibro-epithelial polyps. We concur that establishment of such a policy based solely on this study might not be in the best interest of our patients. First, our study did demonstrate a difference in the rate of malignancy depending on the specialty of the physician clinically diagnosing the lesion. Therefore, any mandated policy would have to take this difference into account and articulate why payment would be restricted for one type of physician and not for another. Second, the intent of our study was to ascertain the degree of diagnostic accuracy of physicians who were excising clinically typical fibroepithelial polyps, not to set policy. We were quite pleased to
Farmer ER, Hood AF. Fibroepithelial Polyps and Pathologic Evaluation-Reply. Arch Dermatol. 1997;133(7):915–916. doi:10.1001/archderm.1997.03890430137024
Customize your JAMA Network experience by selecting one or more topics from the list below.